Filing Analysis
Pyxis Oncology reported the results of its 2026 Annual Meeting of Stockholders held on June 15, 2026. The meeting resulted in the election of three Class II directors and the ratification of Ernst & Young LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 15, 2026, with a quorum of 47,302,035 shares present out of 62,855,464 outstanding shares.
- Mr. Thomas Civik, Dr. Freda Lewis-Hall, M.D., and Mr. Michael A. Metzger were elected as Class II directors until the 2029 Annual Meeting.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Proposal Two (Auditor Ratification) passed with 46,203,257 votes 'For' and 1,076,997 votes 'Against'.
Pyxis Oncology, Inc. announced its financial results for the first quarter ended March 31, 2026, and provided a corporate update. The disclosure was made via a press release furnished under Item 2.02.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026.
- The report was filed on May 14, 2026.
- A corporate update was included in the accompanying press release (Exhibit 99.1).
- The filing was signed by Jitendra Wadhane, Principal Financial and Accounting Officer.
Pyxis Oncology filed an amendment to a previous 8-K to disclose the final Separation and General Release Agreement for former CEO Lara Sullivan, M.D., who departed the company on February 2, 2026, and resigned from the Board on April 29, 2026.
🚩 Red Flags
- Significant severance package including full acceleration of all unvested equity, which can be dilutive or indicative of a negotiated exit to avoid conflict.
📋 Key Facts
- Lara Sullivan, M.D. ceased serving as CEO and principal executive officer effective February 2, 2026.
- Dr. Sullivan resigned from the Board of Directors effective April 29, 2026.
- Separation package includes 18 months of existing salary and up to 12 months of health coverage.
- The Board approved accelerated vesting of all unvested restricted stock units and unvested stock options.
- Post-termination exercise period for accelerated stock options extended to December 31, 2030.
- Agreement includes a one-year non-solicitation covenant for Dr. Sullivan and mutual non-disparagement covenants.
Pyxis Oncology, Inc. announced its full-year 2025 financial results and provided a corporate update on March 23, 2026. The company also released an updated corporate presentation detailing its current strategic outlook.
📋 Key Facts
- Reported financial results for the full year ended December 31, 2025
- Furnished a press release as Exhibit 99.1
- Made an updated corporate presentation available on the company website (Exhibit 99.2)
- The filing was signed by Jitendra Wadhane, Principal Financial and Accounting Officer